Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Rheumatoid Arthritis
•
General Rheumatology
•
JAK Inhibitors
•
Gastroenterology
•
Cirrhosis
•
Hepatology
Do you avoid JAK inhibitors in patients with a history of liver disease including NAFLD or cirrhosis?
Related Questions
Have you utilized JAK inhibitors in patients on dialysis?
How would you approach management of a patient with ankylosing spondylitis who was doing well on tofacitinib, but experienced a STEMI while on therapy?
What patient factors guide your selection of maintenance therapies for a patient with autoimmune hepatitis?
Can Xolair (omalizumab) be safely used in combination with biologics for patients with rheumatic disease?
For patients who do not have access to biologic therapies, what are some csDMARD combination pearls or tips that you have that have particular efficacy in different rheumatologic diseases?
Do you have any experience with compounded iguratimod either as adjunctive therapy or monotherapy for rheumatoid arthritis, Sjogrens, or axial spondyloarthropathy?
Do you always get a baseline chest xray in patients who will be starting methotrexate?
What is the role of inebilizumab in the maintenance treatment of IgG4-related disease?
In a patient with negative Hep B surface Ag, Hep B surface antibody+, and Hep B core antibody+ serologies, do you initiate antiviral prophylaxis (e.g. entecavir) prior to starting rituximab?
What is your approach to differentiating RA-ILD from medication toxicity (I.e. from methotrexate)?
